Obsessive-Compulsive Disorder Treatment Guidelines

Introduction to OCD Treatment

The American College of Physicians recommends that GLP-1 receptor agonists should not be used for the treatment of obsessive-compulsive disorder, as they have no established role in this indication, with their therapeutic mechanisms targeting glucose regulation and weight loss through delayed gastric emptying and increased satiety 1, 2.

Cognitive-Behavioral Therapy with Exposure and Response Prevention (CBT with ERP) is the psychological treatment of choice, demonstrating superior efficacy with a number needed to treat of 3 compared to 5 for SSRIs, according to the International Society for Traumatic Stress Studies 3, 4, 5.
Selective Serotonin Reuptake Inhibitors (SSRIs) represent the first-line pharmacological treatment based on established efficacy, tolerability, safety, and absence of abuse potential, as recommended by the American Psychiatric Association 3, 4, 5.

The treatment algorithm for OCD recommends beginning with either CBT with ERP or SSRI monotherapy, or combining both modalities for optimal outcomes, with patient adherence to between-session ERP homework exercises being the strongest predictor of good outcomes, according to the National Institute of Mental Health 3, 4, 5.
If inadequate response after 8-12 weeks, increase SSRI dose beyond maximum recommended for depression, switch to a different SSRI, or trial clomipramine, as suggested by the European College of Neuropsychopharmacology 4.

Antipsychotic augmentation, particularly brexpiprazole or aripiprazole, shows evidence of efficacy, though only one-third of SSRI-resistant patients demonstrate clinically meaningful response, according to the World Federation of Societies of Biological Psychiatry 3, 4.
Glutamatergic agents, including memantine and N-acetylcysteine, can be considered as augmentation strategies, with multiple RCTs supporting memantine's efficacy when added to SSRIs, as recommended by the International College of Neuropsychopharmacology 3.
Neuromodulation techniques, including repetitive transcranial magnetic stimulation (rTMS) and deep brain stimulation (DBS), are reserved for severe refractory cases, with approximately 30-50% of patients with severe refractory OCD responding to these interventions, according to the National Institute of Neurological Disorders and Stroke 6.

Approximately 50% of OCD patients fail to respond to first-line treatments, requiring aggressive augmentation strategies rather than unproven interventions, as warned by the American Academy of Child and Adolescent Psychiatry 4, 5.
Premature discontinuation of medication leads to high relapse rates; treatment should be maintained for a minimum of 12-24 months after achieving remission, as recommended by the World Health Organization 4, 5.
In patients with comorbid bipolar disorder and OCD, prioritize mood stabilization first with mood stabilizers plus CBT, avoiding SSRIs as monotherapy due to risk of mood destabilization, according to the International Society for Bipolar Disorders 4.